Ubamatamab (REGN4018) is a humanized bispecific antibody targeted against Mucin 16 (MUC16) and CD3. Ubamatamab demonstrates potent antitumor activity.
Ubamatamab (REGN4018; 0.1 pM-10 nM; 48 hours) induces human T cells and cynomolgus T cells to kill OVCAR-3 cells (EC50, 13.6 pM and 30.6 pM, respectively)[1].
Ubamatamab (REGN4018; 0.01-0.5 mg/kg; i.p; on days 6, 10, 13, 16, and 21) potently inhibits growth of intraperitoneal ovarian tumors[1]. Ubamatamab (REGN4018; 0.01-1 mg/kg; i.p; once a week; total of five doses) shows minimal and transient increases in serum cytokines and C-reactive protein, with no overt toxicity[1].
References:
[1]. Alison Crawford, et al. A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.